Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Looking For More Data: Lilly’s Arxxant Gets “Approvable” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly is hopeful that data from an ongoing study will avoid the need for an additional trial.

You may also be interested in...



Lilly To Appeal FDA Action On Arxxant Calling For Additional Clinical Trial

Company says Arxxant clinical data package presents a compelling case for the treatment of diabetic retinopathy.

Lilly To Appeal FDA Action On Arxxant Calling For Additional Clinical Trial

Company says Arxxant clinical data package presents a compelling case for the treatment of diabetic retinopathy.

Arxxant’s Fate In Question After FDA Requests Additional Trial

Lilly may seek a development partner for the diabetic retinopathy treatment to collect the three additional years of efficacy data sought by FDA.

Related Content

Topics

UsernamePublicRestriction

Register

PS064696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel